ASH 2024 | Final analysis from a Phase I trial of asciminib in T315I-mutated CML-CP
Timothy Hughes, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, briefly comments on the final analysis of a Phase I trial (NCT02081378) evaluating the efficacy of asciminib in treating patients with T315I-mutated chronic myeloid leukemia in the chronic phase (CML-CP). Prof. Hughes highlights the promising results of the trial, with a significant number of patients achieving and maintaining a major molecular response (MMR). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We’re reporting the final results of the Phase I trial of the patients with T315I mutations with chronic myeloid leukemia using asciminib at the higher dose of 200 milligrams twice daily. So a lot higher than a standard dose of 80 milligrams once daily. And the results look very impressive. We’re seeing a significant number achieving major molecular response and probably more importantly maintaining major molecular response...
We’re reporting the final results of the Phase I trial of the patients with T315I mutations with chronic myeloid leukemia using asciminib at the higher dose of 200 milligrams twice daily. So a lot higher than a standard dose of 80 milligrams once daily. And the results look very impressive. We’re seeing a significant number achieving major molecular response and probably more importantly maintaining major molecular response. So it looks to be a very promising approach in those patients who have very few options for therapy. It’s probably an approach that has a lower risk of cardiovascular complications compared to ponatinib. And there’s also the potential to lower the dose in patients if there is any level of toxicity and in most cases likely that they will maintain a response.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Ariad: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Novartis: Consultancy, Honoraria, Research Funding.
